myTomorrows

myTomorrows is an international platform that links patients facing unmet medical needs to treatments in development worldwide.

We bridge the gap between patients who are searching for treatment options and the pharmaceutical companies who provide them At myTomorrows, we believe everyone should be able to access the treatment options which are open to them. We strive to make it easier for physicians and their patients with unmet medical needs to find, get information about, and access pre-approval medicines whenever possib

le. We believe that by making the process of accessing pre-approval medicines more transparent, we’ll be able to transform the lives of people all over the world. To contact us, please visit https://www.mytomorrows.com/en/get-in-contact.

20/08/2025

💬 An interview with James Griffin: Living and Advocating with Sickle Cell Disease

In our latest blog, Pre-approval Access Specialist John Massarelli sits down with James Griffin, patient, advocate, and author of ‘Breaking Silence: Living With Sickle Cell Anemia.’ During this conversation, James focuses on his experiences and perspectives on navigating the evolving landscape of sickle cell care in the United States.

💡Sickle cell disease (SCD) is a group of inherited disorders where red blood cells become rigid and crescent-shaped instead of round and flexible. These misshapen cells can block blood flow, causing severe pain, organ damage, and other serious complications. Often considered an “invisible illness”, its pain and symptoms aren’t visible on the outside, leading to misunderstanding, stigma, and delays in urgent care.

James opens up about:
✔️His diagnosis journey and early treatments
✔️The challenges of an invisible illness
✔️Overcoming racial bias in healthcare
✔️ How patients are learning about new therapies
✔️Perspectives on gene therapy for Sickle cell disease
✔️ What BioPharma and providers can do better for the Sickle cell disease community

💚James’s story is not just about living with Sickle cell disease. It is about changing the narrative, pushing for equity, and ensuring patients’ voices guide every step of the care journey.

📖 Read the full interview here: https://eu1.hubs.ly/H0msBzh0

18/08/2025

Are you searching for a role at a company with an important mission? 🌍

Our founder started myTomorrows when he couldn’t find a clinical trial for his dad (who was diagnosed with cancer) in time to help him.

We are a purpose-led company looking for people with endless ambition and an entrepreneurial mindset to come innovate with us.

As a fast-growing startup in Amsterdam with 80+ people, we have 30+ nationalities and many great benefits, like a learning budget, flexible working, and a performance bonus just to name a few.

Join us:
📐 Learn in an ever-evolving, dynamic environment.
🤝 Build up your skills in the healthcare sector.
💚 Know that you’re helping patients worldwide.

✔️Senior Site Manager, Expanded Access Operations https://eu1.hubs.ly/H0mpMkj0
✔️(Interim) Regulatory Affairs & Pharmacovigilance Manager https://eu1.hubs.ly/H0mpMGC0
✔️Regulatory Affairs & Pharmacovigilance Manager https://eu1.hubs.ly/H0mpMx70

Our full list: https://eu1.hubs.ly/H0mpMqP0

13/08/2025

🧠 New Blog: Understanding the Symptoms of Multiple System Atrophy (MSA)

Multiple System Atrophy (MSA) is a progressive neurodegenerative disorder that affects several areas of the brain. Over time, it can impact many vital body functions, including movement, balance, blood pressure regulation, breathing, and even memory and emotions.

But what do these symptoms actually look like in everyday life? And which ones tend to appear first?

For many individuals and families, one of the most challenging parts of an MSA diagnosis is understanding the wide and sometimes unpredictable range of symptoms.

💡 Our latest blog takes a closer look at the symptoms of MSA. It offers an overview of what people may experience, how symptoms can vary, and what changes might occur over time.

📖 We explore:

✔️What is Multiple System Atrophy (MSA)?
✔️How does MSA affect involuntary functions such as blood pressure and bladder control?
✔️What kinds of movement and coordination challenges can appear?
✔️How might MSA affect thinking, memory, and emotions?

🔗 https://eu1.hubs.ly/H0mlHbC0

Whether you are living with MSA, supporting someone who is, or simply looking to learn more, this blog may be a helpful starting point.

💚 This blog is part of our broader effort to provide reliable information on neurodegenerative diseases. For more topics, visit our Neurodegenerative Patient Resource Page, where we’ve gathered insights on conditions like MSA, Parkinson’s, ALS and more.

👉 https://eu1.hubs.ly/H0mlHN_0

13/08/2025

We’re live at ALS Nexus2025! 🚀

The energy here in Dallas is incredible. It’s inspiring to be surrounded by so many voices committed to improving life with ALS: from patients and caregivers to researchers, BioPharma professionals, and advocacy groups.

Dennis Akkaya, Chief Commercial Officer, Madeleine Pagel, PharmD, Senior Patient Navigator, and Terri Ellsworth, Patient Liason, are immersing themselves in the latest ALS research and clinical developments, connecting with BioPharma professionals and PAGs to gain deeper insight into community needs. They’re also exploring new opportunities to collaborate and collecting valuable learnings to bring back to the team.

🎯 Stop by our poster session: “Navigating ALS Clinical Trials: Improving Access and Enrollment Through Patient-Centered Navigation”

📍 Come find us at booth 202 to continue the conversation. Or book a meeting with us: https://eu1.hubs.ly/H0mkQy80

05/08/2025

Just 1 week to go! ⏳

Our Mighties are packing their bags and getting ready to join the ALS community at ALS Nexus 2025 in Dallas, Texas! 🇺🇸

🗓️ 11–14 August 2025
📍 Dallas, TX

Hosted by the The ALS Association, this gathering brings together people from across the ALS community, including PAGs, BioPharma professionals, researchers, and individuals affected by ALS. It’s all about collaborating, sharing ideas, and working together to make ALS a livable disease.

Our Mighties are looking forward to:

✔️Discovering the latest advancements in ALS research and clinical care
✔️Connecting with BioPharma professionals and PAGs to better understand the needs of the ALS community
✔️Explore opportunities for collaboration with passionate professionals committed to improving patient outcomes.
✔️Gathering fresh insights to bring back to the team

🚨Don’t miss our poster presentation: “Navigating ALS Clinical Trials: Improving Access and Enrollment Through Patient-Centered Navigation”

👉Also attending? Visit us at booth 202 or book a meeting with us: https://eu1.hubs.ly/H0m96mm0

04/08/2025

🌐 Begin your week with endless possibilities : Explore our job openings!

We are looking for three people to help deliver a whole new approach to enabling earlier access to all possible treatment options, making a on many lives.

Share our job openings with your network who may be interested, and they could join a fast-growing company of 80+ people, with 30 nationalities, offering great benefits in Amsterdam.

✔️Backend Engineer: https://eu1.hubs.ly/H0m80vz0
✔️Senior Site Manager - Expanded Access Programs: https://eu1.hubs.ly/H0m7Wy30
✔️Interim Regulatory Affairs & Pharmacovigilance Manager: https://eu1.hubs.ly/H0m7-Lt0

👉Our full list: https://eu1.hubs.ly/H0m7VS_0

💚

30/07/2025

Live from San Francisco!

We’re thrilled to be at the Hanson Wade Operationalize: Expanded Access Programs Summit, surrounded by so many professionals working to improve access to investigational and pre-approved therapies.

It’s been an energizing start! 🚀

Our Mighties are actively engaging with Expanded Access teams and industry peers, sharing insights, tackling operational and regulatory challenges, and identifying new opportunities for collaboration to close access gaps.

Our own Dennis kicked off the event as Chair of Day 1, and today at 2pm, Stephanie and John will be taking the stage for our presentation on “Motivations for Pursuing Expanded Access: Strategic Value and Drivers for Stakeholders”

They’ll cover:

→ The strategic benefits of launching Expanded Access Programs early in drug development.
→ Key stakeholder engagement opportunities, including with KOLs, patient advocacy groups, regulators, payers, and internal teams.
→ Operational considerations for effective Expanded Access Programs, including supply, data collection, and regulatory coordination.

📍 Here in San Francisco? Come say hello, or book a meeting with us. We’d love to connect! https://eu1.hubs.ly/H0m4hjm0

21/07/2025

Our Mighties Dennis Akkaya, Chief Commercial Officer, Stephanie Ferket, Director Expanded Access Strategy & Customer Success, and John Massarelli, Pre-approval Access Specialist are getting ready to attend the ‘Hanson Wade Operationalize: Expanded Access Programs Summit West’ in just a week!

🗓️ 29-31 July, 2025
📍 San Francisco, CA

👉Join our workshop on 29th July from 11:30-1:30 PM ‘Expanded Access in Practice: Turning Demand into Strategic Opportunity’.

This practical session will cover the strategic importance of Expanded Access for BioPharma companies developing investigational therapies companies developing investigational therapies, key regulatory and ethical considerations, integrated access strategies aligned with long-term business goals, and much more!

👉 And don’t miss our presentation on July 30th at 2pm!
“Motivations for Pursuing Expanded Access: Strategic Value and Drivers for Stakeholders”

You’ll learn:
✔️The strategic benefits of launching Expanded Access Programs early in drug development.
✔️Identify key stakeholder engagement opportunities, including with KOLs, patient advocacy groups, regulators, payers, and internal teams.
✔️Key operational considerations for effective Expanded Access Programs, including supply, data collection, and regulatory coordination.

🎟️ Use our exclusive discount code MYTOMO20 when you register to get 20% off your ticket.

📅 Don’t forget to book a meeting with us while you're there! https://eu1.hubs.ly/H0lTg3m0

See you in a week!

21/07/2025

Are you searching for a role at a company with an important mission? 🌍

Our founder started myTomorrows when he couldn’t find a clinical trial for his dad (who was diagnosed with cancer) in time to help him.

We are a purpose-led company looking for people with endless ambition and an entrepreneurial mindset to come innovate with us.

As a fast-growing startup in Amsterdam with 80+ people, we have 30+ nationalities and many great benefits, like a learning budget, flexible working, and a performance bonus just to name a few.

Join us:
📐 Learn in an ever-evolving, dynamic environment.
🤝 Build up your skills in the healthcare sector.
💚 Know that you’re helping patients worldwide.

✔️Healthcare Software Engineer: https://eu1.hubs.ly/H0lSVJG0
✔️Senior Site Manager, Expanded Access Operations: https://eu1.hubs.ly/H0lS_zS0
✔️Product Analyst: https://eu1.hubs.ly/H0lS_tl0

👉Our full list: https://eu1.hubs.ly/H0lSNCw0

16/07/2025

🧠 16th July: Glioblastoma Awareness Day

On Glioblastoma awareness day, we come together to raise awareness, stand with those affected, and recognize the ongoing challenges this disease presents.

💡Glioblastoma is the most common type of malignant brain tumor. It begins as a group of abnormal cells in the brain or spinal cord that grow quickly and uncontrollably, often invading healthy brain tissue. As the tumor grows, it can lead to symptoms such as headaches, nausea and vomiting, blurred or double vision, and difficulties with balance or coordination.

Managing glioblastoma usually involves more than one type of treatment, such as surgery, radiation therapy, or chemotherapy. However, even afterwards, recurrence is common, with studies showing that tumors return in approximately 90% of people within two years of their initial diagnosis.

➡️ To learn more about glioblastoma recurrence, its symptoms and available treatment options, read our blog: https://eu1.hubs.ly/H0lMSXC0

💚At myTomorrows, we are proud to stand with the people affected by glioblastoma and their families. We’re committed to supporting this cause by raising awareness, advocating for timely diagnosis, and supporting ongoing research to improve treatment and care.

16/07/2025

Countdown to ALS Nexus! ⏳

In just 4 weeks, our very own Dennis Akkaya, Chief Commercial Officer, Madeleine Pagel, PharmD, Senior Patient Navigator, and Terri Ellsworth, Patient Liason, will be heading to Dallas, Texas, for ALS Nexus 2025! 🇺🇸

🗓️ 11-14 August 2025
📍 Dallas, Texas

Organized by the world’s largest ALS organization, The ALS Association, ALS Nexus brings together leaders from across the ALS community to collaborate, share ideas, and drive progress toward making ALS a livable disease.

We’re proud to be part of this important conversation. 💪

Our Mighties are looking forward to:
✔️Discovering the latest advancements in ALS research and clinical care
✔️Connecting with BioPharma professionals and PAGs to better understand the needs of the ALS community
✔️Explore opportunities for collaboration with passionate professionals committed to improving patient outcomes.
✔️Gathering fresh insights to bring back to the team

💡 Plus, we’ll be:
Presenting our poster: “Navigating ALS Clinical Trials: Improving Access and Enrollment Through Patient-Centered Navigation”

👉 Also attending? Visit us at our booth or book a meeting with us: https://eu1.hubs.ly/H0lN6Pj0

09/07/2025

We’re excited to be attending the 2025 SPEAK LGMD conference, taking place 18–21 July in Orlando, FL! 🚀

Our Mighties Dennis Akkaya, Madeleine Pagel, and Terri Ellsworth will be on-site at our booth 6, connecting with patients, advocacy groups, clinical sites, HCPs, and BioPharma partners. Together, we share a commitment to accelerating research progress for those living with Limb-Girdle Muscular Dystrophy (LGMD).

We’re looking forward to:

✔️Gaining insights into the current LGMD research pipeline from leading biotechs and GRASP-LGMD investigators
✔️Learning from the lived experiences of patients, families, and advocacy groups, and better understanding the challenges they face in discovering and accessing investigational treatments
✔️Engaging in meaningful discussions and exploring collaboration opportunities with passionate professionals committed to improving patient outcomes.

Despite growing efforts in the field, LGMD remains an area of high unmet medical need, highlighting the continued importance of research, partnership, and advocacy. We’re excited to join this important conversation, continue building our relationship with The Speak Foundation, and learn alongside others working to move care forward. 💚

👉Also attending? Book a meeting with us: https://eu1.hubs.ly/H0lCgRD0

Adres

Anthony Fokkerweg 61
Amsterdam
1059CP

Website

https://myTomorrows.com/

Meldingen

Wees de eerste die het weet en laat ons u een e-mail sturen wanneer myTomorrows nieuws en promoties plaatst. Uw e-mailadres wordt niet voor andere doeleinden gebruikt en u kunt zich op elk gewenst moment afmelden.